Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics (NASDAQ: PTIE) rose 82.3% in its July 2000 debut. The ...read more
Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, raised $77 million by offering 5.1 million shares at $15, the high end of the range of $13 to $15. Epizyme plans to list on the NASDAQ under the symbol EPZM. Epizyme...read more
Six US IPOs were able to raise $970 million last week including two $330 million + deals. Three IPOs offered double-digit first-day pops, including e-commerce platform ChannelAdvisor (32%), which continued a streak of ten consecutive enterprise software...read more
Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues
Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics (NASDAQ: PTIE) rose 82.3% in its July 2000 debut. The ...read more
US IPO Recap: May ends with 30 pricings, two billion-dollar deals set for June
30 IPO...read more
Epizyme prices IPO at $15, the high end of the range
Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, raised $77 million by offering 5.1 million shares at $15, the high end of the range of $13 to $15. Epizyme plans to list on the NASDAQ under the symbol EPZM. Epizyme...read more
US IPO Recap: IPO market continues torrid pace with six pricings, 12 new filers
Six US IPOs were able to raise $970 million last week including two $330 million + deals. Three IPOs offered double-digit first-day pops, including e-commerce platform ChannelAdvisor (32%), which continued a streak of ten consecutive enterprise software...read more